Movement Alert｜SBP GROUP Intraday Rise 3.43% in Regular Trading, hepatitis B pipeline updates and recent buybacks supported sentiment

Market Focus10-20

On October 20, SBP GROUP recorded an Intraday Rise of 3.43% in Regular Trading, with the stock trading at HK$5.42 and turnover of HK$89.14 million.

The move coincided with continued market attention on the company’s hepatitis B pipeline after it disclosed that TQ-A3334, a TLR7 agonist developed by subsidiary Chia Tai Tianqing, was selected as a late-breaking abstract for presentation at the AASLD meeting, while partnered product Bepirovirsen was selected for two oral presentations and eight poster presentations.

Additional support came from recent capital management actions. The company repurchased 7.4 million shares on October 13 for about HK$39.56 million and 8.0 million shares on October 14 for about HK$41.32 million, with the repurchased shares intended for cancellation. Sector strength also provided a favorable backdrop, with peers including HANSOH PHARMA, CSPC PHARMA, HENGRUI PHARMA, ALEBUND-B, and HUTCHMED all advancing.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment